Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 343,902,784
  • Shares Outstanding, K 1,765,868
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • 60-Month Beta 0.63
  • Price/Sales 6.28
  • Price/Cash Flow 12.24
  • Price/Book 50.14
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 28.60% ( -0.14%)
  • Historical Volatility 14.75%
  • IV Percentile 99%
  • IV Rank 94.00%
  • IV High 29.42% on 04/12/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 1.00
  • Today's Volume 7,403
  • Volume Avg (30-Day) 12,579
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 345,439
  • Open Int (30-Day) 341,428

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 2.95
  • Number of Estimates 9
  • High Estimate 2.97
  • Low Estimate 2.92
  • Prior Year 2.95
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
189.62 +2.50%
on 09/26/24
198.97 -2.32%
on 10/01/24
-5.00 (-2.51%)
since 09/10/24
3-Month
167.26 +16.20%
on 07/16/24
199.95 -2.80%
on 09/03/24
+26.21 (+15.59%)
since 07/10/24
52-Week
135.85 +43.06%
on 11/09/23
199.95 -2.80%
on 09/03/24
+45.46 (+30.53%)
since 10/10/23

Most Recent Stories

More News
3 Magnificent Dividend Stocks to Buy in October

These dividend stocks are great picks as the fall season gets underway.

ABT : 115.62 (-0.28%)
ABBV : 194.35 (-0.21%)
AMGN : 321.01 (-0.43%)
PFE : 29.34 (-2.82%)
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?

Declining earnings haven't scared billionaire investors away from this stock.

ABBV : 194.35 (-0.21%)
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now

These companies can lend growth and dividend returns to a long-term investor's portfolio.

KHC : 34.83 (+0.46%)
ABBV : 194.35 (-0.21%)
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More

This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication. The FDA also granted priority review designation to AstraZeneca’s AZN label...

AZN : 76.87 (-0.82%)
LLY : 910.69 (-0.98%)
ABBV : 194.35 (-0.21%)
REGN : 999.02 (-1.30%)
SNY : 54.77 (-0.69%)
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

AbbVie ABBV announced in a regulatory filing that it is lowering its previously issued guidance for 2024 adjusted earnings per share by 4 cents per share to account for acquired in-process research and...

BAYRY : 7.3535 (-1.89%)
AZN : 76.87 (-0.82%)
LLY : 910.69 (-0.98%)
ABBV : 194.35 (-0.21%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 1.2400 (-5.34%)
BGNE : 239.38 (-0.42%)
HCM : 19.91 (-0.85%)
ABBV : 194.35 (-0.21%)
ONC.TO : 1.70 (-6.08%)
ELVN : 26.97 (-4.40%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 1.2400 (-5.34%)
BGNE : 239.38 (-0.42%)
HCM : 19.91 (-0.85%)
ABBV : 194.35 (-0.21%)
ONC.TO : 1.70 (-6.08%)
ELVN : 26.97 (-4.40%)
5 Best Dividend Growth Stocks to Buy in October

These five stocks are known for their generous dividend programs and robust business models.

MSFT : 415.84 (-0.39%)
COST : 893.63 (-1.70%)
BAC : 39.97 (-0.55%)
AXP : 270.47 (-0.35%)
ABBV : 194.35 (-0.21%)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 117.53 (+0.45%)
GMAB : 23.71 (+0.25%)
LLY : 910.69 (-0.98%)
ABBV : 194.35 (-0.21%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug...

ANVS : 8.00 (-0.62%)
NVO : 117.53 (+0.45%)
LLY : 910.69 (-0.98%)
ABBV : 194.35 (-0.21%)
PFE : 29.34 (-2.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 196.57
2nd Resistance Point 195.69
1st Resistance Point 195.02
Last Price 194.35
1st Support Level 193.48
2nd Support Level 192.60
3rd Support Level 191.93

See More

52-Week High 199.95
Last Price 194.35
Fibonacci 61.8% 175.46
Fibonacci 50% 167.90
Fibonacci 38.2% 160.34
52-Week Low 135.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar